JP2004529934A - 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用 - Google Patents

抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用 Download PDF

Info

Publication number
JP2004529934A
JP2004529934A JP2002584909A JP2002584909A JP2004529934A JP 2004529934 A JP2004529934 A JP 2004529934A JP 2002584909 A JP2002584909 A JP 2002584909A JP 2002584909 A JP2002584909 A JP 2002584909A JP 2004529934 A JP2004529934 A JP 2004529934A
Authority
JP
Japan
Prior art keywords
composition
microtubule agent
carrier
polysaccharide
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002584909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529934A5 (https=
Inventor
ウィリアム エル． ハンター，
デイビット エム． グラベット，
リチャード ティー． リギンズ，
フィリップ エム． トレイキス，
Original Assignee
アンジオテック ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジオテック ファーマシューティカルズ，インコーポレイテッド filed Critical アンジオテック ファーマシューティカルズ，インコーポレイテッド
Publication of JP2004529934A publication Critical patent/JP2004529934A/ja
Publication of JP2004529934A5 publication Critical patent/JP2004529934A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002584909A 2001-05-01 2002-05-01 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用 Pending JP2004529934A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28801701P 2001-05-01 2001-05-01
PCT/CA2002/000676 WO2002087563A2 (en) 2001-05-01 2002-05-01 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009029172A Division JP2009161543A (ja) 2001-05-01 2009-02-10 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用

Publications (2)

Publication Number Publication Date
JP2004529934A true JP2004529934A (ja) 2004-09-30
JP2004529934A5 JP2004529934A5 (https=) 2005-12-22

Family

ID=23105397

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002584909A Pending JP2004529934A (ja) 2001-05-01 2002-05-01 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
JP2009029172A Pending JP2009161543A (ja) 2001-05-01 2009-02-10 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009029172A Pending JP2009161543A (ja) 2001-05-01 2009-02-10 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用

Country Status (5)

Country Link
US (1) US20020192280A1 (https=)
EP (1) EP1387676A2 (https=)
JP (2) JP2004529934A (https=)
CA (1) CA2445763A1 (https=)
WO (1) WO2002087563A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533302A (ja) * 2011-11-15 2014-12-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
JP2015502351A (ja) * 2011-11-15 2015-01-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ オートクレーブ可能なシクロスポリンａ２型の懸濁剤
JP2015034172A (ja) * 2007-12-31 2015-02-19 サムヤン バイオファーマシューティカルズ コーポレイション タキサン含有両親媒性ブロック共重合体ミセル組成物及びその製造方法
JP2015527391A (ja) * 2012-09-06 2015-09-17 ナンヤン テクノロジカル ユニヴァーシティー ヒアルロン酸をベースとする薬物送達システム
US9795562B2 (en) 2007-12-31 2017-10-24 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491312C (en) * 2002-07-15 2011-05-31 Alcon, Inc. Bioerodible film for ophthalmic drug delivery
US8110209B2 (en) * 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
WO2004058238A1 (en) * 2002-12-23 2004-07-15 Alcon, Inc. Use of cathepsin k inhibitors for the treatment of glaucoma
EP1608359A4 (en) * 2003-04-03 2011-08-17 Jessie L-S Au DRUG-LOADING PARTICLES TARGETING TUMORS
US7273445B2 (en) * 2003-04-30 2007-09-25 Board Of Trustees Of The University Of Illinois Intraocular brachytherapy device and method
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
US20080057128A1 (en) * 2003-07-18 2008-03-06 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
EP1670838B1 (en) * 2003-10-10 2015-12-09 Samyang Biopharmaceuticals Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1684819A2 (en) * 2003-11-20 2006-08-02 Angiotech International Ag Polymer compositions and methods for their use
SK285346B6 (sk) * 2004-01-14 2006-11-03 Pleuran, S. R. O. Spôsob prípravy fungálneho glukánového hydrogélu s antibakteriálnymi a imunostimulačnými účinkami
CA2536096A1 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
US7901707B2 (en) * 2004-03-15 2011-03-08 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
EP1865982A1 (en) * 2005-04-06 2007-12-19 Bioartificial Gel Technologies Inc. Hydrogel composition for modulation of topical inflammatory response
US20080247987A1 (en) * 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof
US8426381B2 (en) * 2005-09-09 2013-04-23 Lucas Meyer Cosmetics Canada Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
ITMI20051826A1 (it) * 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
FR2900575B1 (fr) * 2006-05-05 2008-10-17 Anteis Sa Gel biocompatible a liberation controlee, son procede de preparation et son utilisation
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008132233A1 (en) * 2007-05-01 2008-11-06 Kuros Biosurgery Ag Composition, methods and kits for prevention of adhesion
US8158185B2 (en) * 2007-10-04 2012-04-17 Bunge Oils, Inc. Controlled viscosity oil composition and method of making
NZ586343A (en) * 2007-12-24 2012-03-30 Sun Pharma Advanced Res Co Ltd Nanodispersion comprising taxane derivatives, fatty acids and sterols
US8608632B1 (en) 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
DK2227257T3 (da) 2008-01-07 2013-09-30 Salutaris Medical Devices Inc Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet
EP2153836A1 (en) * 2008-08-04 2010-02-17 Polichem S.A. Film-forming liquid formulations for drug release to hair and scalp
CN102802624A (zh) 2009-06-19 2012-11-28 太阳医药高级研发有限公司 药物的纳米分散体以及它的制备方法
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US8399590B2 (en) * 2009-10-07 2013-03-19 Akzo Nobel Chemicals International B.V. Superhydrophilic amphiphilic copolymers and processes for making the same
US11173106B2 (en) * 2009-10-07 2021-11-16 Johnson & Johnson Consumer Inc. Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener
US8258250B2 (en) 2009-10-07 2012-09-04 Johnson & Johnson Consumer Companies, Inc. Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof
US8858577B2 (en) 2010-05-19 2014-10-14 University Of Utah Research Foundation Tissue stabilization system
US8945156B2 (en) 2010-05-19 2015-02-03 University Of Utah Research Foundation Tissue fixation
ES2385995B2 (es) * 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
US8852214B2 (en) 2011-02-04 2014-10-07 University Of Utah Research Foundation System for tissue fixation to bone
WO2012170504A2 (en) * 2011-06-06 2012-12-13 The Cleveland Clinic Foundation Treatment of extracellular matrix to reduce inflammation
US10226417B2 (en) * 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
ITRM20120169A1 (it) * 2012-04-19 2013-10-20 Consiglio Nazionale Ricerche Dispositivo di rilascio di specie chimiche a controllo ottico
US10390935B2 (en) 2012-07-30 2019-08-27 Conextions, Inc. Soft tissue to bone repair devices, systems, and methods
US10835241B2 (en) 2012-07-30 2020-11-17 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US11944531B2 (en) 2012-07-30 2024-04-02 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US10219804B2 (en) 2012-07-30 2019-03-05 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US9427309B2 (en) 2012-07-30 2016-08-30 Conextions, Inc. Soft tissue repair devices, systems, and methods
US11957334B2 (en) 2012-07-30 2024-04-16 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US11253252B2 (en) 2012-07-30 2022-02-22 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US11583384B2 (en) 2014-03-12 2023-02-21 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
WO2015138760A1 (en) 2014-03-12 2015-09-17 Conextions, Inc. Soft tissue repair devices, systems, and methods
US12508019B2 (en) 2014-03-12 2025-12-30 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
WO2016071365A1 (en) * 2014-11-03 2016-05-12 Spherium Biomed, S.L. Topical pharmaceutical compositions of paclitaxel
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
US11696822B2 (en) 2016-09-28 2023-07-11 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US11547397B2 (en) 2017-12-20 2023-01-10 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
US12102317B2 (en) 2017-12-20 2024-10-01 Conextions, Inc. Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone
SG11202005672PA (en) * 2018-01-05 2020-07-29 Crititech Inc Treatment of bladder cancer by local administration of taxane particles
CN118303936A (zh) 2018-02-20 2024-07-09 科内克思申斯股份有限公司 用于将软组织固定到骨的医疗装置系统
PL240632B1 (pl) * 2018-04-06 2022-05-09 Univ Jagiellonski Zastosowanie nanokapsuły z ciekłym rdzeniem olejowym w terapii przeciwnowotworowej
KR102639246B1 (ko) 2019-04-29 2024-02-22 삼성디스플레이 주식회사 표시장치
EP4122445A1 (en) * 2021-07-19 2023-01-25 Pk Med Dosage form for intra-articular injection comprising colchicine for use in the treatment of crystal-and non-crystal associated acute inflammatory arthritis
CN114395144B (zh) * 2022-01-28 2024-09-06 上海瑞凝生物科技有限公司 一种透明质酸-聚乙二醇-层状二氧化硅复合水凝胶及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505587A (ja) * 1994-08-02 1998-06-02 マサチューセッツ インスティテュート オブ テクノロジー 固形腫瘍を処置するための化学療法薬剤の制御された局所送達
WO1998036776A2 (en) * 1997-02-20 1998-08-27 Matrix Pharmaceutical, Inc. Gel delivery vehicles for anticellular proliferative agents
WO1999013914A1 (en) * 1997-09-18 1999-03-25 Human Rt. Pharmaceutical compositions containing plasma protein
JP2000511161A (ja) * 1996-05-24 2000-08-29 アンジオテック ファーマシュウティカルズ，インコーポレイテッド 身体通路の疾患を処置または予防するための組成物および方法
JP2001503785A (ja) * 1996-12-02 2001-03-21 アンジオテック ファーマシューティカルズ，インコーポレイテッド 炎症性疾患を処置または予防するための組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008109A (en) * 1984-05-25 1991-04-16 Vestar, Inc. Vesicle stabilization
US5244672A (en) * 1988-12-02 1993-09-14 Coletica Composition containing liposomes stabilized by a stabilizing support based on atelocollagen and glycosaminoglycans
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SE9301422D0 (sv) * 1993-04-28 1993-04-28 Kabi Pharmacia Ab Method and means for inhibiting posterior capsule opacification
BR9509590A (pt) * 1994-11-04 1997-12-23 Polymun Scient Immunbio Forsch Aplicação de sod em liposomas
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6890901B2 (en) * 1996-09-27 2005-05-10 Jagotec Ag Hyaluronic drug delivery system
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
IN191203B (https=) * 1999-02-17 2003-10-04 Amarnath Prof Maitra
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505587A (ja) * 1994-08-02 1998-06-02 マサチューセッツ インスティテュート オブ テクノロジー 固形腫瘍を処置するための化学療法薬剤の制御された局所送達
JP2000511161A (ja) * 1996-05-24 2000-08-29 アンジオテック ファーマシュウティカルズ，インコーポレイテッド 身体通路の疾患を処置または予防するための組成物および方法
JP2001503785A (ja) * 1996-12-02 2001-03-21 アンジオテック ファーマシューティカルズ，インコーポレイテッド 炎症性疾患を処置または予防するための組成物および方法
WO1998036776A2 (en) * 1997-02-20 1998-08-27 Matrix Pharmaceutical, Inc. Gel delivery vehicles for anticellular proliferative agents
WO1999013914A1 (en) * 1997-09-18 1999-03-25 Human Rt. Pharmaceutical compositions containing plasma protein

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015034172A (ja) * 2007-12-31 2015-02-19 サムヤン バイオファーマシューティカルズ コーポレイション タキサン含有両親媒性ブロック共重合体ミセル組成物及びその製造方法
US9795562B2 (en) 2007-12-31 2017-10-24 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
JP2014533302A (ja) * 2011-11-15 2014-12-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
JP2015502351A (ja) * 2011-11-15 2015-01-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ オートクレーブ可能なシクロスポリンａ２型の懸濁剤
JP2015527391A (ja) * 2012-09-06 2015-09-17 ナンヤン テクノロジカル ユニヴァーシティー ヒアルロン酸をベースとする薬物送達システム

Also Published As

Publication number Publication date
CA2445763A1 (en) 2002-11-07
US20020192280A1 (en) 2002-12-19
WO2002087563A2 (en) 2002-11-07
JP2009161543A (ja) 2009-07-23
WO2002087563A3 (en) 2003-10-30
EP1387676A2 (en) 2004-02-11

Similar Documents

Publication Publication Date Title
JP2004529934A (ja) 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
US20070213393A1 (en) Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
CN101011576B (zh) 治疗或预防炎症性疾病的组合物和方法
US6495579B1 (en) Method for treating multiple sclerosis
US20080153900A1 (en) Compositions and methods for treating or preventing imflammatory diseases
US20080124400A1 (en) Microparticles With High Loadings Of A Bioactive Agent
AU2002302218B2 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
AU2002302218A1 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
AU2007203381A1 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
AU771994B2 (en) Compositions and methods for treating or preventing inflammatory diseases
AU2006220416B2 (en) Compositions and methods for treating or preventing inflammatory diseases
AU2004200715C1 (en) Compositions and methods for treating or preventing inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091118